DK2828282T3 - Biomarkører - Google Patents
Biomarkører Download PDFInfo
- Publication number
- DK2828282T3 DK2828282T3 DK13764431.6T DK13764431T DK2828282T3 DK 2828282 T3 DK2828282 T3 DK 2828282T3 DK 13764431 T DK13764431 T DK 13764431T DK 2828282 T3 DK2828282 T3 DK 2828282T3
- Authority
- DK
- Denmark
- Prior art keywords
- ghrsp
- pneumonia
- fragment
- adhf
- seq
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/63—Motilins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/26—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/12—Pulmonary diseases
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/32—Cardiovascular disorders
- G01N2800/325—Heart failure or cardiac arrest, e.g. cardiomyopathy, congestive heart failure
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Endocrinology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Peptides Or Proteins (AREA)
Claims (14)
1. Fremgangsmåde til evaluering af pneumoni og akut dekompenseret hjertesvigt (ADHF) hos et individ, hvilken fremgangsmåde omfatter udførelse af en assay-fremgangsmåde, der er konfigureret til at detektere et ghrelinsignalpeptidfragment ifølge SEQ ID NO: 3 eller SEQ ID NO: 4 i en kropsfluidprøve opnået fra individet for at tilvejebringe et assay-resultat; og korrelering af assay-resultatet med tilstedeværelsen eller status for pneumoni og akut dekompenseret hjertesvigt (ADHF) hos individet.
2. Fremgangsmåde ifølge krav 1, hvor (a) korreleringstrinnet omfatter korrelering af assay-resultatet med én eller flere af risikostratificering, stadieinddeling, klassificering og monitorering af eksistensen eller status af pneumoni og ADFIF hos individet; (b) korreleringstrinnet omfatter tildeling af et behandlingsregimen til individet baseret på assay-resultatet; (c) korreleringstrinnet omfatter evaluering af et klinisk resultat efter et behandlingsregimen for pneumoni og ADFIF hos individet; og/eller (d) assay-resultatet er en målt koncentration af et ghrelinsignalpeptidfragment, og korreleringstrinnet omfatter sammenligning af koncentrationen med en tærskelkoncentration.
3. Fremgangsmåde ifølge krav 1 eller krav 2, hvor (a) individet udvælges til evaluering af pneumoni baseret på ét eller flere symptomer på pneumoni, herunder hoste med spytproduktion, feber, pleuraexsudat, skarp brystsmerte ved inspiration og stakåndethed; og/eller (b) individet udvælges for evaluering af ADFIF baseret på ét eller flere symptomer på ADFIF, herunder åndenød (dyspnø), ødem og træthed.
4. Fremgangsmåde ifølge krav 1 eller krav 2, hvor korreleringstrinnet omfatter vurdering af, om pneumonien og ADFIF bedres eller forværres hos individet baseret på assay-resultatet.
5. Fremgangsmåde ifølge krav 2(d), hvor tærsklen er en koncentration af ghrelinsignalpeptidfragmentet: (a) opnået fra individet på et tidligere tidspunkt; (b) opnået fra en normal individpopulation; (c) opnået fra en population med pneumonia og ADFIF; og/eller (d) udvalgt til at skelne fra en population af individer en første subpopulation med pneumoni og ADHF i forhold til en anden subpopulation, der ikke har pneumoni og ADHF.
6. Fremgangsmåde ifølge et hvilket som helst af kravene 1 til 5, hvor assay-fremgangsmåden omfatter et ghrelinsignalpeptidfragment-bindingsmiddel, der binder: (a) GHRsp (1-9) (SEQ ID NO: 3) eller (b) GHRsp (1-10) (SEQ ID NO: 4).
7. Fremgangsmåde ifølge krav 6, hvor niveauet af ghrelinsignalpeptidfragment detekteres i prøven ved binding af et ghrelinsignalpeptidfragment til et bindingsmiddel, der selektivt binder GHRsp (1-9) (SEQ ID NO: 3).
8. Fremgangsmåde ifølge krav 6 eller 7, hvor ghrelinsignalpeptidfragment-bindingsmidlet er et polyklonalt, monoklonalt, bispecifikt, kimærisk eller humaniseret antistof eller antigenbindingsfragment deraf.
9. Fremgangsmåde ifølge krav 8, hvor ghrelinsignalpeptidfragment eller bindingsmidlet er mærket med en detekterbar markør.
10. Fremgangsmåde ifølge et hvilket som helst af kravene 1 til 9, hvor den biologiske prøve er fra en kredsløbskilde, såsom blod, plasma, serum, spyt, interstitiel fluid eller urin, eller fra en vævsprøve.
11. Fremgangsmåde ifølge et hvilket som helst af kravene 1 til 10, hvor niveauet af ghrelinsignalpeptidfragment måles ved anvendelse af massespektroskopi eller ved anvendelse af et assay udvalgt fra RIA, ELISA, immunfluorometrisk assay og immunradiometrisk assay.
12. Fremgangsmåde ifølge et hvilket som helst af kravene 1 til 11, der endvidere omfatter måling af niveauet af én eller flere non-GHRsp-markører af pneumoni, ADHF eller pneumoni og ADHF, eventuelt hvor non-GHRsp-markøren er udvalgt fra gruppen bestående af procalcitonin (PCT), udløsende receptor udtrykt på myeloide celler-1, kreativt protein (CRP), immunglobuliner og proinflammatoriske cytokiner, hjerne-natriuretisk protein (BNP), N-terminalproBNP (NT-BNP), blod-urea-nitrogen (BUN), pankreatisk stenprotein og troponin.
13. Assay-fremgangsmåde til detektering af pneumoni og akut dekompenseret hjertesvigt (ADHF) hos et individ, hvilket assay omfatter: (a) binding af et ghrelinsignalpeptidfragment ifølge SEQ ID NO: 3 eller SEQ ID NO: 4 opnået fra eller i en biologisk prøve; og (b) bestemmelse af tilstedeværelsen eller mængden af bundet ghrelinsignalpeptidfragment; og (c) korrelering af tilstedeværelsen eller mængden af det bundne ghrelinsignalpeptidfragment med en reference- eller kontrolværdi; hvor en afvigelse i tilstedeværelsen eller mængden af bundet ghrelinsignalpeptidfragment i prøven fra reference- eller kontrolværdien indikerer, at individet har pneumoni og ADHF.
14. Assay-fremgangsmåde ifølge krav 13, hvor: (a) mængden af ghrelinsignalpeptidfragment højere end kontrolmængden indikerer pneumoni og ADHF; (b) fremgangsmåden anvendes til at evaluere eller monitorere et respons på behandling af pneumoni og ADHF hos et individ, hvor en ændring i det målte niveau af ghrelinsignalpeptidfragment fra kontrolniveauet indikerer et respons på behandlingen; og/eller (c) assayet omfatter måling af niveauet af ghrelinsignalpeptidfragment i talrige biologiske prøver individet.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261613311P | 2012-03-20 | 2012-03-20 | |
| PCT/NZ2013/000043 WO2013141716A1 (en) | 2012-03-20 | 2013-03-15 | Biomarkers |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2828282T3 true DK2828282T3 (da) | 2018-03-05 |
Family
ID=49223053
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK13764431.6T DK2828282T3 (da) | 2012-03-20 | 2013-03-15 | Biomarkører |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US10114028B2 (da) |
| EP (1) | EP2828282B1 (da) |
| CN (1) | CN104470942B (da) |
| DK (1) | DK2828282T3 (da) |
| ES (1) | ES2661516T3 (da) |
| IN (1) | IN2014DN08537A (da) |
| WO (1) | WO2013141716A1 (da) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104107419A (zh) * | 2014-05-29 | 2014-10-22 | 四川大学华西医院 | 胃饥饿素在预防或/和治疗放射性肺损伤中的用途 |
| KR20200128413A (ko) * | 2018-03-02 | 2020-11-12 | 에보니크 오퍼레이션즈 게엠베하 | 오보트랜스페린을 결정함으로써 동물에서의 장 장벽 기능상실을 검출하기 위한 시험관내 방법 |
| US11446009B2 (en) | 2018-12-11 | 2022-09-20 | Eko.Ai Pte. Ltd. | Clinical workflow to diagnose heart disease based on cardiac biomarker measurements and AI recognition of 2D and doppler modality echocardiogram images |
| US11931207B2 (en) | 2018-12-11 | 2024-03-19 | Eko.Ai Pte. Ltd. | Artificial intelligence (AI) recognition of echocardiogram images to enhance a mobile ultrasound device |
| US12400762B2 (en) | 2018-12-11 | 2025-08-26 | Eko.Ai Pte. Ltd. | Automatic clinical workflow that recognizes and analyzes 2D and doppler modality echocardiogram images for automated cardiac measurements and diagnosis of cardiac amyloidosis and hypertrophic cardiomyopathy |
| US12001939B2 (en) | 2018-12-11 | 2024-06-04 | Eko.Ai Pte. Ltd. | Artificial intelligence (AI)-based guidance for an ultrasound device to improve capture of echo image views |
| US12322100B2 (en) | 2018-12-11 | 2025-06-03 | Eko.Ai Pte. Ltd. | Automatic clinical workflow that recognizes and analyzes 2D and doppler modality echocardiogram images for automated cardiac measurements and grading of aortic stenosis severity |
| CN109825567B (zh) * | 2018-12-27 | 2022-06-10 | 博奥生物集团有限公司 | 肺炎诊断用circRNA生物标志物及应用、引物和试剂 |
| CN111951215A (zh) * | 2020-06-30 | 2020-11-17 | 数坤（北京）网络科技有限公司 | 一种图像检测方法、装置及计算机可读存储介质 |
| WO2025040754A1 (en) * | 2023-08-22 | 2025-02-27 | Roche Diagnostics Gmbh | Monitoring of cardiovascular markers in interstitial fluid and its application in assessment of heart failure |
| CN117393154B (zh) * | 2023-12-12 | 2024-03-01 | 中国中医科学院医学实验中心 | 基于血清全通路氧化脂质组学筛选心力衰竭生物标志物的方法及应用 |
Family Cites Families (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4196265A (en) | 1977-06-15 | 1980-04-01 | The Wistar Institute | Method of producing antibodies |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5310687A (en) | 1984-10-31 | 1994-05-10 | Igen, Inc. | Luminescent metal chelate labels and means for detection |
| GB8800077D0 (en) | 1988-01-05 | 1988-02-10 | Ciba Geigy Ag | Novel chimeric antibodies |
| US5843708A (en) | 1988-01-05 | 1998-12-01 | Ciba-Geigy Corporation | Chimeric antibodies |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| US5028535A (en) | 1989-01-10 | 1991-07-02 | Biosite Diagnostics, Inc. | Threshold ligand-receptor assay |
| US5939272A (en) | 1989-01-10 | 1999-08-17 | Biosite Diagnostics Incorporated | Non-competitive threshold ligand-receptor assays |
| US5744101A (en) | 1989-06-07 | 1998-04-28 | Affymax Technologies N.V. | Photolabile nucleoside protecting groups |
| US5922615A (en) | 1990-03-12 | 1999-07-13 | Biosite Diagnostics Incorporated | Assay devices comprising a porous capture membrane in fluid-withdrawing contact with a nonabsorbent capillary network |
| JPH05506218A (ja) | 1990-05-07 | 1993-09-16 | イムノメデイツクス・インコーポレイテツド | 一価の抗体フラグメントの改良された放射性標識方法 |
| JPH05504841A (ja) | 1990-09-14 | 1993-07-22 | バイオサイト・ダイアグノスティックス・インコーポレイテッド | リガンドレセプター及びリガンドのコンプレックスに対する抗体及びリガンド―レセプターアッセーでのそれらの用途 |
| DE69129154T2 (de) | 1990-12-03 | 1998-08-20 | Genentech, Inc., South San Francisco, Calif. | Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften |
| US5221685A (en) | 1991-02-01 | 1993-06-22 | Ube Industries, Ltd. | Thiazoline derivative, process for preparing the same and chemical for controlling noxious organisms containing the same |
| US5955377A (en) | 1991-02-11 | 1999-09-21 | Biostar, Inc. | Methods and kits for the amplification of thin film based assays |
| WO1992018868A1 (en) | 1991-04-10 | 1992-10-29 | Biosite Diagnostics Incorporated | Crosstalk inhibitors and their uses |
| ATE195808T1 (de) | 1991-04-12 | 2000-09-15 | Biosite Diagnostics Inc | Neue konjugate und testverfahren für die gleichzeitige bestimmung von multiplen liganden |
| US6143576A (en) | 1992-05-21 | 2000-11-07 | Biosite Diagnostics, Inc. | Non-porous diagnostic devices for the controlled movement of reagents |
| US6019944A (en) | 1992-05-21 | 2000-02-01 | Biosite Diagnostics, Inc. | Diagnostic devices and apparatus for the controlled movement of reagents without membranes |
| US5494829A (en) | 1992-07-31 | 1996-02-27 | Biostar, Inc. | Devices and methods for detection of an analyte based upon light interference |
| US5605798A (en) | 1993-01-07 | 1997-02-25 | Sequenom, Inc. | DNA diagnostic based on mass spectrometry |
| EP1347493A3 (en) | 1993-05-28 | 2005-11-23 | Baylor College Of Medicine | Method and apparatus for desorption and ionization of analytes |
| US5824799A (en) | 1993-09-24 | 1998-10-20 | Biosite Diagnostics Incorporated | Hybrid phthalocyanine derivatives and their uses |
| ATE224053T1 (de) | 1993-11-12 | 2002-09-15 | Inverness Medical Switzerland | Vorrichtung zum ablesen von teststreifen |
| EP0653639B1 (en) | 1993-11-12 | 2000-03-22 | Unilever Plc | Analytical devices and methods of use thereof |
| US5647124A (en) | 1994-04-25 | 1997-07-15 | Texas Instruments Incorporated | Method of attachment of a semiconductor slotted lead to a substrate |
| GB9419267D0 (en) | 1994-09-23 | 1994-11-09 | Unilever Plc | Assay devices |
| US5792294A (en) | 1995-11-16 | 1998-08-11 | Otis Elevator Company | Method of replacing sheave liner |
| US5719600A (en) | 1995-12-12 | 1998-02-17 | Hewlett-Packard Company | Gradient calculation system and method |
| US6113855A (en) | 1996-11-15 | 2000-09-05 | Biosite Diagnostics, Inc. | Devices comprising multiple capillarity inducing surfaces |
| US5947124A (en) | 1997-03-11 | 1999-09-07 | Biosite Diagnostics Incorporated | Diagnostic for determining the time of a heart attack |
| US6057098A (en) | 1997-04-04 | 2000-05-02 | Biosite Diagnostics, Inc. | Polyvalent display libraries |
| NZ516848A (en) | 1997-06-20 | 2004-03-26 | Ciphergen Biosystems Inc | Retentate chromatography apparatus with applications in biology and medicine |
| GB9717926D0 (en) | 1997-08-22 | 1997-10-29 | Micromass Ltd | Methods and apparatus for tandem mass spectrometry |
| AU2463299A (en) | 1998-01-23 | 1999-08-09 | Analytica Of Branford, Inc. | Mass spectrometry from surfaces |
| US6406921B1 (en) | 1998-07-14 | 2002-06-18 | Zyomyx, Incorporated | Protein arrays for high-throughput screening |
| US6831060B2 (en) | 1999-05-07 | 2004-12-14 | Genentech, Inc. | Chimpanzee erythropoietin (CHEPO) polypeptides and nucleic acids encoding the same |
| US6784154B2 (en) | 2001-11-01 | 2004-08-31 | University Of Utah Research Foundation | Method of use of erythropoietin to treat ischemic acute renal failure |
| EP1464069A2 (en) | 2001-12-21 | 2004-10-06 | Sense Proteomic Limited | Probe for mass spectrometry |
| AUPS169202A0 (en) | 2002-04-11 | 2002-05-16 | Goetze, Jens Peter | Neuropeptide assay |
| US6780645B2 (en) | 2002-08-21 | 2004-08-24 | Lifescan, Inc. | Diagnostic kit with a memory storing test strip calibration codes and related methods |
| US7045366B2 (en) | 2003-09-12 | 2006-05-16 | Ciphergen Biosystems, Inc. | Photocrosslinked hydrogel blend surface coatings |
| US20040091961A1 (en) | 2002-11-08 | 2004-05-13 | Evans Glen A. | Enhanced variants of erythropoietin and methods of use |
| EP1616181B1 (en) | 2003-04-17 | 2009-08-12 | Vermillion, Inc. | Polypeptides related to natriuretic peptides and methods of their identification and use |
| ZA200510282B (en) | 2003-07-02 | 2007-03-28 | Genentech Inc | Compositions and methods for the diagnosis and treatment of tumor |
| WO2005052593A1 (en) | 2003-10-29 | 2005-06-09 | The University Of Leicester | Detection |
| US7423139B2 (en) | 2004-01-20 | 2008-09-09 | Insight Biopharmaceuticals Ltd. | High level expression of recombinant human erythropoietin having a modified 5′-UTR |
| NZ552667A (en) | 2004-07-23 | 2009-04-30 | Inst Medical W & E Hall | Therapeutic and diagnostic agents |
| AU2005267720B2 (en) | 2004-08-05 | 2012-02-23 | Genentech, Inc. | Humanized anti-cmet antagonists |
| JP2006292623A (ja) | 2005-04-13 | 2006-10-26 | Univ Of Dundee | 心不全における突然死のマーカー |
| EP1731910A1 (en) | 2005-06-07 | 2006-12-13 | F. Hoffmann-La Roche Ag | Use of NT-proANP and NT-proBNP for diagnosing cardiac diseases |
| NZ576061A (en) | 2006-09-07 | 2013-02-22 | Otago Innovation Ltd | Biomarkers |
| GB0712670D0 (en) | 2007-06-29 | 2007-08-08 | King S College London | Isolated peptides and uses thereof |
| CA2715921A1 (en) * | 2008-03-12 | 2009-09-17 | Otago Innovation Limited | Biomarkers |
| WO2011048168A1 (en) * | 2009-10-21 | 2011-04-28 | Pronota N.V. | Biomarker for diagnosis, prediction and/or prognosis of acute heart failure and uses thereof |
-
2013
- 2013-03-15 US US13/844,449 patent/US10114028B2/en not_active Expired - Fee Related
- 2013-03-15 WO PCT/NZ2013/000043 patent/WO2013141716A1/en not_active Ceased
- 2013-03-15 CN CN201380026197.XA patent/CN104470942B/zh not_active Expired - Fee Related
- 2013-03-15 EP EP13764431.6A patent/EP2828282B1/en not_active Not-in-force
- 2013-03-15 ES ES13764431.6T patent/ES2661516T3/es active Active
- 2013-03-15 IN IN8537DEN2014 patent/IN2014DN08537A/en unknown
- 2013-03-15 DK DK13764431.6T patent/DK2828282T3/da active
Also Published As
| Publication number | Publication date |
|---|---|
| EP2828282A4 (en) | 2015-08-26 |
| US20130296240A1 (en) | 2013-11-07 |
| US10114028B2 (en) | 2018-10-30 |
| EP2828282A1 (en) | 2015-01-28 |
| IN2014DN08537A (da) | 2015-05-15 |
| CN104470942A (zh) | 2015-03-25 |
| WO2013141716A1 (en) | 2013-09-26 |
| ES2661516T3 (es) | 2018-04-02 |
| CN104470942B (zh) | 2018-12-14 |
| EP2828282B1 (en) | 2017-12-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2828282T3 (da) | Biomarkører | |
| AU2009224114B2 (en) | Biomarkers | |
| JP6889780B2 (ja) | 遺伝子バリアントを認識する抗体 | |
| CN102947707B (zh) | 前胃泌素和肝病理 | |
| US20190100576A1 (en) | Signal biomarkers | |
| JP2011514156A (ja) | 急性冠動脈障害のためのバイオマーカー | |
| AU2016382408A1 (en) | Diagnosis of unstable angina | |
| CA2715914C (en) | Insulin signal peptide fragment biomarkers | |
| US20180156822A1 (en) | Biomarker for cardiac disorders | |
| CA2771954A1 (en) | Pneumonia biomarkers | |
| WO2019212364A1 (en) | Test for heart failure | |
| WO2025172467A1 (en) | Endotrophin assay | |
| HK1229884B (zh) | 用於心脏病症的生物标记物 |